[GLP-1 (7-36) amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM].
Karolinska Institute, Stockholm, Suède.
M
M
Gutniak
D000818:Animals; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005934:Glucagon; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use*
D010446:Peptide Fragments; C055453:glucagon-like peptide 1 (7-36)amide; D004763:Glucagon-Like Peptides; D052216:Glucagon-Like Peptide 1; D005934:Glucagon
GLP-1 (7-36) amide [GLIP-glucagon like insulinotropic peptide] comme traitement potentiel du DNID.